Transcat has successfully finalized the acquisition of 100% of the share capital of the target, marking a significant expansion of its technical advisory capabilities within the life sciences sector. This strategic transaction represents a definitive move to incorporate high-margin calibration optimization services into the group’s broader service segment. The strategic rationale for the move centers on the acquirer’s objective to broaden its technical operational depth in asset and reliability management for pharmaceutical and biotechnology clients. By incorporating this technical specialist, the organization reinforces its ability to offer proprietary, software-enabled solutions that drive immediate margin accretion. The partnership is designed to leverage the target’s established footprint in Ireland and the United States to accelerate the scaling of specialized consulting services across the combined global customer base. This integration facilitates the creation of a uniquely integrated metrology and asset management platform, providing the strategic depth required to navigate the complex regulatory landscapes of the medical device and clinical sectors. The transaction includes structured performance incentives to ensure the continued leadership of the founding management team within the group's decentralized operating model.

NEXA ENTERPRISE, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN discount to the 11.3x average currently observed in the Business Services sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.